While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.

The latest trading session saw Novavax (NVAX) ending at $12.80, denoting a -0.85% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.28%. Meanwhile ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

在近期的疫苗市场动态中，诺瓦瓦克斯医药 (Novavax)的疫苗上市引发了广泛关注。该公司的新冠疫苗已在美国获得批准，旨在防止至少12岁以上人群感染新冠，然而，疫苗概念股的表现却显得涨跌不一。这一现象不仅反映了市场对疫苗的信心，也揭示了更为复杂的投资心理。

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The Food and Drug Administration (FDA) has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted.

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club – a term ...

Buying $1000 In NVAX: If an investor had bought $1000 of NVAX stock 5 years ago, it would be worth $2,000.00 today based on a ...

Novavax, Inc. (NVAX) announced Friday that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to ...